DMALL (02586) released its interim results, with a profit attributable to shareholders of 109 million yuan, an increase of 60.85% year-on-year.
Duodian Shuzhi (02586) announced its interim results for the six months ending June 30, 2026, with revenue of RMB 1.155 billion, an increase of 7.05% year-on-year; the profit attributable to equity shareholders is RMB 109 million, an increase of 60.85% year-on-year; earnings per share are RMB 0.12.
DMALL (02586) announced its interim results for the six months ending June 30, 2026, with the group achieving revenue of RMB 1.155 billion, a year-on-year increase of 7.05%. The profit attributable to equity shareholders was RMB 109 million, a year-on-year increase of 60.85%; earnings per share stood at RMB 0.12.
The announcement stated that the revenue growth was primarily due to the ongoing expansion of the group's AI retail core solutions business.
Backed by years of deep cultivation in retail digitalization, the group has built a foundation of online business, online data, and online processes, systematically advancing the practical exploration of AI agents in retail scenarios, and officially initiating a strategic upgrade from a "retail digital solution provider" to a "retail AI agent service provider." Unlike general AI applications, the groups AI capabilities are not detached from the retail business system; they are deeply embedded in retail operations and business systems, promoting AI's evolution from a "support tool" to "operational capability."
In the first half of 2026, the group focused on its core business sectors to achieve high-quality growth. Total revenue reached RMB 1.155 billion, representing a year-on-year growth of 7.1%, with revenue from the core business of AI retail core solutions amounting to RMB 647 million, a year-on-year increase of 24.0%. In the first half of the year, AI-related income was RMB 36.8 million. The groups operational efficiency further improved, with profit for the period being RMB 103 million, a significant year-on-year increase of 66.2%, while adjusted net profit reached RMB 118 million, up 52.7% year-on-year. In the first half of 2026, the group continued to deepen its service with benchmark clients, while simultaneously advancing new customer development. During this period, the group served 415 clients, with a net revenue retention rate of 112%.
During the reporting period, under the AI retail core solutions segment, the group primarily provided the advanced AI-enabled DmallOS system. The group offers two fee models for clients to choose from: charging a certain percentage based on the total value of customer goods transactions processed by the groups system (that is, the total value of goods sold during a specific period, regardless of whether the goods have been settled or returned) or charging a subscription fee based on individual client needs or financial conditions. Additionally, for clients requiring customized implementation, software development, and maintenance services, the group provides tailored solutions. Revenue from the AI retail core solutions increased by 24.0% from RMB 522 million during the six months ending June 30, 2025, to RMB 647 million during the reporting period, primarily due to increased business volume from the group's independent customer base.
Related Articles

ORIENTAL EXPL (00430) issues a profit warning, expecting that integrated profit attributable to shareholders for the first half of the year will decrease to approximately HK$3 million to HK$3.2 million.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-7590 injection has obtained the Drug Clinical Trial Approval Notification.

CHINA RES LAND (01109) reported a cumulative contract sales amount of approximately 130.6 billion yuan for the first seven months, an increase of 5.7% year-on-year.
ORIENTAL EXPL (00430) issues a profit warning, expecting that integrated profit attributable to shareholders for the first half of the year will decrease to approximately HK$3 million to HK$3.2 million.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-7590 injection has obtained the Drug Clinical Trial Approval Notification.

CHINA RES LAND (01109) reported a cumulative contract sales amount of approximately 130.6 billion yuan for the first seven months, an increase of 5.7% year-on-year.

RECOMMEND





